| Project/Area Number |
24791190
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Dermatology
|
|---|
| Research Institution | University of Occupational and Environmental Health, Japan |
|---|
Principal Investigator |
SAWADA Yu 産業医科大学, 医学部, 非常勤医師 (40551867)
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 成人T細胞性白血病／リンパ腫 / 皮疹 / 治療 / 成人T細胞性白血病/リンパ腫 / 皮疹治療 |
|---|
| Research Abstract |
Approximately 50% of adult T-cell leukemia/lymphoma (ATLL) patients have skin involvement, and the smoldering, skin lesion-bearing cases are often treated with various skin-directed therapies, such as phototherapy and radiation therapy. Daily oral administration of etoposide plus prednisolone (EP) is also used for smoldering-type ATLL. However, it remains unclear whether these therapies improve the patients survival.
We retrospectively analyzed the prognosis of smoldering, skin lesion-bearing ATLL patients, who were treated, as the first therapy, with one skin-directed therapy, oral EP alone, or combination of skin-directed therapy and oral EP. The multivariate analysis revealed that the hazard ratios (HRs) for the OS and the PFS of the combination therapy were significantly lower than those of the skin-directed therapy. These results suggest that the combination of skin-directed therapy and oral EP improves the clinical outcome of patients with skin involved smoldering ATLL.
|
